uploads///Infectious diseases

An Overview of Johnson & Johnson’s Infectious Diseases Business

By

Oct. 25 2018, Updated 7:32 a.m. ET

Revenue trends

Johnson & Johnson’s (JNJ) infectious diseases business generated revenue of $823.0 million in the third quarter compared to $813.0 million in the third quarter of 2017, reflecting a 1.2% YoY (year-over-year) rise.

In the third quarter, in the US and international markets, the business generated revenues of $345.0 million and $478.0 million, respectively, reflecting a ~2.3% YoY fall and a 3.9% YoY rise.

Article continues below advertisement

The infectious diseases business’s revenue totaled $2.5 billion in the first nine months of the year, reflecting a ~6.3% YoY rise. The business could significantly boost the company’s revenue growth, which in turn could boost the share price of the SPDR Dow Jones Industrial Average ETF (DIA). Johnson & Johnson makes up ~3.65% of DIA’s total portfolio holdings.

Edurant’s revenue trends

Johnson & Johnson’s Edurant generated revenue of $202.0 million in the third quarter, reflecting a ~4.1% YoY rise.

Edurant’s net revenue in the first nine months of the year totaled $623.0 million, including revenue of $42.0 million and $581.0 million from its sales in the US and international markets, respectively.

In the third quarter, in the international markets, Edurant witnessed ~6.8% YoY operational growth.

Prezista, Prezcobix, Rezolsta, and Symtuza

In the third quarter, JNJ’s anti-HIV drugs Prezista, Prezcobix, Rezolsta, and Symtuza combined generated total net revenue of $490.0 million compared to $467.0 million in the third quarter of 2017, reflecting ~4.9% YoY growth.

In the third quarter, in the US and international markets, the Prezista group generated net revenues of $297.0 million and $193.0 million, respectively, reflecting rises of ~3.5% and ~7.2% YoY.

In the international market, the Prezista group generated operational growth of 12.4% YoY.

The Prezista group’s net revenue totaled $1.46 billion in the first nine months of 2018 compared to $1.35 billion in the same period of the previous year, reflecting ~8.1% YoY growth.

Prezista, Prezcobix, Rezolsta, and Symtuza could face competition from Gilead Sciences’ (GILD) Genvoya, Odefsey, and Descovy, which reported revenues of $1.16 billion, $385.0 million, and $403.0 million, respectively, in the second quarter.

Advertisement

More From Market Realist

  • CONNECT with Market Realist
  • Link to Facebook
  • Link to Twitter
  • Link to Instagram
  • Link to Email Subscribe
Market Realist Logo
Do Not Sell My Personal Information

© Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.